RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1,878
- 试验地点
- 167
- 主要终点
- Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time
研究概览
简要总结
The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new ischaemic cardiovascular events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Dabigatran etexilate 50mg
twice daily dosing,
干预措施: dabigatran etexilate (Drug)
Dabigatran etexilate 75mg
twice daily dosing, patients with moderate renal impairment allocated 50mg bid
干预措施: dabigatran etexilate (Drug)
Dabigatran etexilate 110mg
twice daily dosing, patients with moderate renal impairment allocated 75mg bid
干预措施: dabigatran etexilate (Drug)
dabigatran etexilate 150mg
twice daily dosing, patients with moderate renal impairment allocated 110mg bid
干预措施: dabigatran etexilate (Drug)
placebo
matched placebo
干预措施: placebo (Drug)
结局指标
主要结局
Number of Participants Displaying the Composite of Major and Clinically Relevant Minor Bleeding Events During Total Observation Time
时间窗: 6 month treatment period + 2 week post treatment follow up
International Society Thrombosis and Haemostasis (ISTH) definition of a major bleed, and clinically relevant minor bleed. A bleeding event was considered as major if it was fatal, was a symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), or caused a fall in haemoglobin level of ≥2 g/dL (≥1.24 mmol/L), or led to transfusion of ≥2 units of whole blood or red cells. All non major bleeding events were classified as minor bleeds; minor bleeds were subdivided in clinically relevant minor bleeds and not clinically relevant minor bleeds. A CRBE was defined as an acute or subacute clinically overt bleed that did not meet the criteria of a major bleed but either lead to hospital admission and/or a physician guided medical or surgical treatment and/or a change in antithrombotic therapy (including interruption or discontinuation of study drug).
次要结局
- Number of Participants With Any Reduction of D-dimer Concentration(at 1 week and 4 weeks)
- Composite of Cardiovascular Death (CVD) With Non Fatal Myocardial Infarction (MI) and Non Haemorrhagic Stroke and All Cause Death (ACD), Non Fatal MI, Severe Recurrent Ischaemia (SRI) and Non Haemorrhagic Stroke During Six Months Treatment(6 month treatment period + 2 week post treatment follow up)
- Individual Occurrence of Death (Cardiovascular and All-cause), Non-fatal MI, Severe Recurrent Ischaemia and Non-haemorrhagic Stroke During Six Months of Treatment(6 month treatment period + 2 week post treatment follow up)
- Change From Baseline in log10 D-dimer After 1 and 4 Weeks(Baseline and at 1 week and 4 weeks)
- Number of Participants With Bleeding Events During Total Observation Time(6 month treatment period + 2 week post treatment follow up)
- Laboratory Analyses(6 month treatment period + 2 week post treatment follow up)
